Renal Denervation Market Size is likely to witness a major upsurge from 2022-2028, owing to the beneficial effects of renal denervation therapy on cardiovascular physiology and other associated pathologies, such as the decreased burden of cardiac tachyarrhythmia. In addition, its evolution as a safe and efficacious invasive procedure to reduce blood pressure in patients with resistive hypertension will also fuel industry growth in the years ahead. Renal denervation refers to a minimally invasive procedure that adopts radiofrequency ablation technique to burn the nerves in the walls of renal arteries to reduce nerve activity and in turn, decrease blood pressure. This procedure is designed to treat hypertension in patients who are unable to control high blood pressure after taking a regimen of at least three medications at the same time.
Rising burden of chronic diseases like obesity among both children and adults will power renal denervation market trends through 2022-2028. As per the WHO’s statistics, over 39 million children aged below 5 years were overweight in 2020. This condition is likely to push the demand for renal nerve denervation therapy, as high leptin levels in obese people can trigger the growth of blood vessels in the hypothalamus, thereby causing hypertension. An increase in the level of daily alcohol consumption will further drive the market share, as regular drinking is linked with high blood pressure.
Ultrasound ablation will emerge as a key technology segment for the renal denervation market by 2028. The segmental expansion is driven by the high effectiveness of catheter-based renal denervation procedures conducted with ultrasound technology in lowering blood pressure across a spectrum of hypertension severity. Based on product, the EnligHTN renal denervation system segment will hold a considerable share over the forecast spell, due to the escalating implementation of clinical studies to examine its efficacy in treating drug-resistant, uncontrolled hypertension.
Latin America renal denervation market is poised to amass considerable profits by 2028, which can be credited to the high burden of disability and death caused by low-density-lipoprotein cholesterol levels in Brazil. Since high blood pressure is linked with high cholesterol levels, its growing incidence, alongside the mounting healthcare spending, could bolster the product demand in the region. However, reduced access to cardiac rehabilitation due to factors like lack of insurance coverage and low income in the country may create a hindrance to overall market dynamics over the forthcoming years.
Some of the players in the renal denervation market include Covidien PLC (Medtronic), Ablative Solutions, Inc., Bioscience Webster, Inc., Recor Medical, Inc. (Otsuka Holdings), Boston Scientific Corporation, CardioSonic, Abbott, and Kona Medical, among others. Innovative product launches and collaborations are some of the initiatives being undertaken by these market players to reinforce their presence in the global market. For instance, in December 2020, ReCor Medical, Inc. received the U.S. FDA’s Breakthrough Device Designation for its innovative Paradise Ultrasound Renal Denervation System, designed to ablate the renal nerve using ultrasound energy.
The economic crisis triggered by the novel coronavirus pandemic has posed massive disruptions to the healthcare systems worldwide. Various health agencies have revealed that the pandemic could halt two decades of progress towards Universal Health Coverage, which may have hampered the renal denervation industry. Despite these setbacks, several contributory factors to increased levels of hypertension, including high alcohol consumption during the pandemic may help the market recover over the foreseeable future. According to the National Institute on Alcohol Abuse and Alcoholism, the quantity of alcohol sold in 15 U.S. states rose by 4% during January 2020-August 2020 as compared to a year earlier, which could increase risk of hypertension and stimulate the use of renal denervation devices.
Market, by Technology
Market, by Product
Market, by End-Use
The above information is provided for the following regions and fcountries: